Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes
- PMID: 22242683
- DOI: 10.1021/ja208518u
Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes
Abstract
Protein kinases (PKs) play an important role in the development and progression of cancer by regulating cell growth, survival, invasion, metastasis, and angiogenesis. Dasatinib (BMS-354825), a dual Src/Abl inhibitor, is a promising therapeutic agent with oral bioavailability. It has been used for the treatment of imatinib-resistant chronic myelogenous leukemia (CML). Most kinase inhibitors, including Dasatinib, inhibit multiple cellular targets and do not possess exquisite cellular specificity. Recent efforts in kinase research thus focus on the development of large-scale, proteome-wide chemical profiling methods capable of rapid identification of potential cellular (on- and off-) targets of kinase inhibitors. Most existing approaches, however, are still problematic and in many cases not compatible with live-cell studies. In this work, we have successfully developed a cell-permeable kinase probe (DA-2) capable of proteome-wide profiling of potential cellular targets of Dasatinib. In this way, highly regulated, compartmentalized kinase-drug interactions were maintained. By comparing results obtained from different proteomic setups (live cells, cell lysates, and immobilized affinity matrix), we found DA-2 was able to identify significantly more putative kinase targets. In addition to Abl and Src family tyrosine kinases, a number of previously unknown Dasatinib targets have been identified, including several serine/threonine kinases (PCTK3, STK25, eIF-2A, PIM-3, PKA C-α, and PKN2). They were further validated by pull-down/immunoblotting experiments as well as kinase inhibition assays. Further studies are needed to better understand the exact relevance of Dasatinib and its pharmacological effects in relation to these newly identified cellular targets. The approach developed herein should be amenable to the study of many of the existing reversible drugs/drug candidates.
Similar articles
-
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005. Clin Ther. 2007. PMID: 18158072 Review.
-
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32. doi: 10.1158/1078-0432.CCR-05-0757. Clin Cancer Res. 2005. PMID: 16203784
-
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980. Clin Cancer Res. 2006. PMID: 17020995
-
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. Leukemia. 2009. PMID: 19039322
-
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27. Clin Ther. 2012. PMID: 22285209 Review.
Cited by
-
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas.NPJ Precis Oncol. 2022 Oct 21;6(1):74. doi: 10.1038/s41698-022-00310-7. NPJ Precis Oncol. 2022. PMID: 36271142 Free PMC article.
-
How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins.Mol Pharmacol. 2021 Jul;100(1):1-6. doi: 10.1124/molpharm.120.000186. Epub 2021 May 3. Mol Pharmacol. 2021. PMID: 33941662 Free PMC article.
-
Molecular determinants of drug response in TNBC cell lines.Breast Cancer Res Treat. 2020 Jan;179(2):337-347. doi: 10.1007/s10549-019-05473-9. Epub 2019 Oct 26. Breast Cancer Res Treat. 2020. PMID: 31655920 Free PMC article.
-
Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes.Sci Adv. 2018 Nov 21;4(11):eaau8408. doi: 10.1126/sciadv.aau8408. eCollection 2018 Nov. Sci Adv. 2018. PMID: 30474060 Free PMC article.
-
B-cell receptor signaling as a driver of lymphoma development and evolution.Semin Cancer Biol. 2013 Dec;23(6):410-21. doi: 10.1016/j.semcancer.2013.09.001. Epub 2013 Sep 20. Semin Cancer Biol. 2013. PMID: 24060900 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous